Browse LIMA1

Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm. Cell junction, focal adhesion. Cytoplasm, cytoskeleton. Note=This cytoskeletal protein co-localizes with actin stress fibers and focal adhesion plaques.
Domain PF00412 LIM domain
Function

Binds to actin monomers and filaments. Increases the number and size of actin stress fibers and inhibits membrane ruffling. Inhibits actin filament depolymerization. Bundles actin filaments, delays filament nucleation and reduces formation of branched filaments.

> Gene Ontology
 
Biological Process GO:0007015 actin filament organization
GO:0008064 regulation of actin polymerization or depolymerization
GO:0008154 actin polymerization or depolymerization
GO:0010639 negative regulation of organelle organization
GO:0030042 actin filament depolymerization
GO:0030832 regulation of actin filament length
GO:0030834 regulation of actin filament depolymerization
GO:0030835 negative regulation of actin filament depolymerization
GO:0031529 ruffle organization
GO:0032535 regulation of cellular component size
GO:0032956 regulation of actin cytoskeleton organization
GO:0032970 regulation of actin filament-based process
GO:0032984 macromolecular complex disassembly
GO:0043241 protein complex disassembly
GO:0043242 negative regulation of protein complex disassembly
GO:0043244 regulation of protein complex disassembly
GO:0043624 cellular protein complex disassembly
GO:0051017 actin filament bundle assembly
GO:0051261 protein depolymerization
GO:0051493 regulation of cytoskeleton organization
GO:0051494 negative regulation of cytoskeleton organization
GO:0061572 actin filament bundle organization
GO:0090066 regulation of anatomical structure size
GO:1901879 regulation of protein depolymerization
GO:1901880 negative regulation of protein depolymerization
Molecular Function GO:0003779 actin binding
GO:0003785 actin monomer binding
GO:0045296 cadherin binding
GO:0050839 cell adhesion molecule binding
GO:0051015 actin filament binding
GO:0098631 protein binding involved in cell adhesion
GO:0098632 protein binding involved in cell-cell adhesion
GO:0098641 cadherin binding involved in cell-cell adhesion
Cellular Component GO:0001725 stress fiber
GO:0005903 brush border
GO:0005913 cell-cell adherens junction
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0015629 actin cytoskeleton
GO:0030055 cell-substrate junction
GO:0032153 cell division site
GO:0032154 cleavage furrow
GO:0032155 cell division site part
GO:0032432 actin filament bundle
GO:0042641 actomyosin
GO:0097517 contractile actin filament bundle
GO:0097610 cell surface furrow
GO:0098862 cluster of actin-based cell projections
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LIMA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LIMA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR Second most enriched score: 0.57 Sensitive to T cell-mediated killing
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LIMA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.1690.646
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.7280.756
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2350.888
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.4340.227
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.6910.774
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.1070.973
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2030.682
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3230.872
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.070.975
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.0930.469
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.4620.531
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.2340.0205
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LIMA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.14.170.339
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.15.160.373
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.509.50.492
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131115.4015.40.482
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LIMA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LIMA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LIMA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LIMA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LIMA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LIMA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLIMA1
NameLIM domain and actin binding 1
Aliases EPLIN; epithelial protein lost in neoplasm beta; SREBP3; 1110021C24Rik; sterol regulatory element binding pr ......
Chromosomal Location12q13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LIMA1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.